معرفی
Xiaoqi Liu, PhD, is a Professor and Chair in the Department of Toxicology and Cancer Biology at the University of Kentucky, where he also holds the Lucille P. Markey Endowed Chair in Oncology Research. His research focuses on understanding the molecular basis of cancer to develop novel targeted therapies.
Research Interests:
- Molecular mechanisms of oncogenesis
- Polo-like kinase 1 (Plk1) signaling in cancer
- Chemoresistance and DNA damage response
- Targeted therapy for prostate, pancreatic, lung cancers, and melanoma
- Combination therapies involving kinase inhibitors and epigenetic drugs
His recent publications highlight a strong focus on Plk1’s role in regulating tumor suppressors (PTEN, TSC1, Numb), DNA repair proteins (Mre11, MDC1), and its potential to enhance the efficacy of PARP, BET, and mTOR inhibitors. The work spans molecular oncology, cell signaling, and preclinical therapeutic development.
Scientific Awards and Honors:
- Lucille P. Markey Endowed Chair in Oncology Research
Xiaoqi Liu leads an active research laboratory investigating Plk1 as a therapeutic target. While specific grant details and student mentorship are not listed, his extensive publication record and leadership role suggest a well-funded and productive research program. The LIU Research Lab uses biochemistry, cell biology, and mouse genetics to explore cancer mechanisms and treatment strategies.
